Michael J. Buege

416 total citations
15 papers, 225 citations indexed

About

Michael J. Buege is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Michael J. Buege has authored 15 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 6 papers in Genetics. Recurrent topics in Michael J. Buege's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (2 papers). Michael J. Buege is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (2 papers). Michael J. Buege collaborates with scholars based in United States, Australia and Italy. Michael J. Buege's co-authors include Adam J. DiPippo, Courtney D. DiNardo, Tim Peterson, Samuel L Aitken, Jack Brown, Jason A. Sprowl, Su Sien Ong, Aksana Vasilyeva, Alex Sparreboom and Eberhard Schlatter and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and BioMed Research International.

In The Last Decade

Michael J. Buege

13 papers receiving 220 citations

Peers

Michael J. Buege
Eiju Negoro Japan
Ayad Al-Katib United States
Charlotte Dupuis France
Z. Shen China
Sumita Saluja India
Béatrice Delmas-Marsalet France
Ana Rodrigues Portugal
Jennifer Yui United States
Che Ry Hong South Korea
Kazutaka Takagi Japan
Eiju Negoro Japan
Michael J. Buege
Citations per year, relative to Michael J. Buege Michael J. Buege (= 1×) peers Eiju Negoro

Countries citing papers authored by Michael J. Buege

Since Specialization
Citations

This map shows the geographic impact of Michael J. Buege's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Buege with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Buege more than expected).

Fields of papers citing papers by Michael J. Buege

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Buege. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Buege. The network helps show where Michael J. Buege may publish in the future.

Co-authorship network of co-authors of Michael J. Buege

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Buege. A scholar is included among the top collaborators of Michael J. Buege based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Buege. Michael J. Buege is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Villa, Diego, Aixiang Jiang, Carlo Visco, et al.. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 7(16). 4576–4585. 11 indexed citations
2.
Buege, Michael J., Esther Drill, Steven M. Horwitz, et al.. (2023). Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. European Journal Of Haematology. 111(1). 96–102.
3.
Qualls, David, Michael J. Buege, Phuong Dao, et al.. (2022). Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study. Blood. 140(Supplement 1). 787–789. 16 indexed citations
4.
Buege, Michael J., et al.. (2021). IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Clinical Lymphoma Myeloma & Leukemia. 21(12). 873–878. 1 indexed citations
5.
Buege, Michael J., Phuong Dao, Philip Caron, et al.. (2021). Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Leukemia & lymphoma. 63(4). 876–884. 1 indexed citations
6.
Buege, Michael J., et al.. (2020). Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Annals of Pharmacotherapy. 54(9). 879–898. 4 indexed citations
7.
Buege, Michael J., et al.. (2020). IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Blood. 136(Supplement 1). 10–10.
8.
Peterson, Tim, et al.. (2019). Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma. Annals of Pharmacotherapy. 54(6). 577–582. 20 indexed citations
9.
Buege, Michael J., Bryan Do, Hans C. Lee, et al.. (2019). Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. Cancer Treatment and Research Communications. 21. 100159–100159. 13 indexed citations
10.
Buege, Michael J., Adam J. DiPippo, & Courtney D. DiNardo. (2018). Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers. 10(6). 187–187. 27 indexed citations
11.
Buege, Michael J., Jack Brown, & Samuel L Aitken. (2017). Solithromycin: A novel ketolide antibiotic. American Journal of Health-System Pharmacy. 74(12). 875–887. 21 indexed citations
12.
Buege, Michael J., et al.. (2016). Implantable cardioverter defibrillator pocket infection caused by Stenotrophomonas maltophilia. International Journal of Case Reports and Images. 7(9). 579–579. 1 indexed citations
13.
Buege, Michael J., et al.. (2015). Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review. Reviews on Recent Clinical Trials. 10(4). 326–339. 10 indexed citations
14.
Pabla, Navjotsingh, Alice A. Gibson, Michael J. Buege, et al.. (2015). Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proceedings of the National Academy of Sciences. 112(16). 5231–5236. 81 indexed citations
15.
Koehler, Till, et al.. (2015). Changes of the eSheath Outer Dimensions Used for Transfemoral Transcatheter Aortic Valve Replacement. BioMed Research International. 2015. 1–6. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eiju Negoro Breakdown of academic impact, for papers by Ayad Al-Katib Breakdown of academic impact, for papers by Charlotte Dupuis Breakdown of academic impact, for papers by Z. Shen Breakdown of academic impact, for papers by Sumita Saluja Breakdown of academic impact, for papers by Béatrice Delmas-Marsalet Breakdown of academic impact, for papers by Ana Rodrigues Breakdown of academic impact, for papers by Jennifer Yui Breakdown of academic impact, for papers by Che Ry Hong Breakdown of academic impact, for papers by Kazutaka Takagi
Rankless by CCL
2026